Boston Scientific (NYSE:BSX) reported Q2 adjusted earnings of $0.53 per share, up from $0.44 a year earlier.
Analysts polled by Capital IQ expected $0.49.
Net sales for the quarter ended June 30 were $3.60 billion, compared with $3.24 billion a year earlier.
Analysts surveyed by Capital IQ expected $3.50 billion.
For Q3, the medical technology company said it expects adjusted EPS of $0.46 to $0.48. Analysts surveyed by Capital IQ project $0.48. The company expects net sales for the quarter to grow from 8.5% to 10.5% compared with a year earlier.
For 2023, the company said it now expects adjusted EPS of $1.96 to $2, from the prior outlook of $1.90 to $1.96 Analysts polled by Capital IQ expect $1.96.The company also raised its net sales growth outlook for the year to an 11% to 12% increase, from its previously announced range of 8.5% to 11%.